NYSE:PFE

Pfizer - PFE Stock Forecast, Price & News

$40.80

+0.42 (+1.04%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $40.28
▼
$40.83
50-Day Range: $39.39
▼
$45.07
52-Week Range: $39.23
▼
$56.32

Volume: 22.83 million shs
Average Volume: 23.08 million shs
Market Capitalization: $230.29 billion

P/E Ratio: 7.45
Dividend Yield: 4.02%
Price Target: $50.38

Institutional Ownership

Pfizer MarketRank™ Forecast

Analyst Rating: Hold
2.36 Rating Score
Upside/Downside: 23.5% Upside
$50.38 Price Target
Short Interest: Healthy
0.78% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: 0.05
Based on 23 Articles This Week
Insider Trading: Acquiring Shares
$5 M Bought Last Quarter
Proj. Earnings Growth: 15.15%
From $3.30 to $3.80 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.38 out of 5 stars

Medical Sector

8th out of 1,004 stocks

Pharmaceutical Preparations Industry

3rd out of 489 stocks

3.2

Analyst's Opinion

Consensus Rating
Pfizer has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.38, Pfizer has a forecasted upside of 23.5% from its current price of $40.80.
Amount of Analyst Coverage
Pfizer has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.78% of the outstanding shares of Pfizer have been sold short.
Short Interest Ratio / Days to Cover
Pfizer has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pfizer has recently increased by 14.68%, indicating that investor sentiment is decreasing significantly.

5.0

Dividend Strength

Dividend Leadership
Pfizer is a leading dividend payer. It pays a dividend yield of 4.10%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Pfizer has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Pfizer is 29.93%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Pfizer will have a dividend payout ratio of 43.16% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pfizer has received a 68.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "Apixaban", and "Pneumococcal vaccines" products. See details.
Environmental Sustainability
The Environmental Impact score for Pfizer is -1.95.

2.3

News and Social Media Coverage

News Sentiment
Pfizer has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 23 news articles for Pfizer this week, compared to 21 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 3 reddit mentions for Pfizer this week, compared to 5 mentions on an average week.
Search Interest
Only 239 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
101 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 55% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pfizer insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.05% of the stock of Pfizer is held by insiders.
Percentage Held by Institutions
67.62% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Pfizer are expected to grow by 15.15% in the coming year, from $3.30 to $3.80 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pfizer is 7.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.61.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pfizer is 7.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.48.
Price to Earnings Growth Ratio
Pfizer has a PEG Ratio of 1.35. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Pfizer has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

March 28, 2023 | marketbeat.com

Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data (PFE)

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

March 28, 2023 | marketbeat.com

Don't Be Fooled by These 3 Value Traps (PFE)

Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold.

March 31, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 28, 2023 | marketbeat.com

Smartsheet Can Bolster Workflow Ecosystems and Your Portfolio (PFE)

Cloud-based collaborative work management software provider Smartsheet Inc. (NASDAQ: SMAR) is an under-the-radar name growing at 35%.

March 27, 2023 | marketbeat.com

BioNTech Is Ripe For A Rebound In 2023 (PFE)

BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.

March 22, 2023 | marketbeat.com

3 Dividend Contenders to Buy Now for Long-Term Gains Later (PFE)

Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later

March 21, 2023 | marketbeat.com

Why did Sarepta Therapeutics Stock Plummet? (PFE)

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

March 18, 2023 | marketbeat.com

MarketBeat Week in Review – 3/13 - 3/17 (PFE)

The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week

March 31, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 15, 2023 | marketbeat.com

Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock

Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock

March 8, 2023 | marketbeat.com

Schrodinger is an AI-Powered Drug Discovery Developer to Watch (PFE)

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

March 2, 2023 | dividendstocks.com

AbbVie Stock: ABBV Overview and Dividend Potential (PFE)

March 30, 2023 | finance.yahoo.com

Starter Stock Portfolio: 15 Safe Stocks To Buy

March 30, 2023 | benzinga.com

Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug

March 30, 2023 | americanbankingnews.com

Pfizer Inc. (NYSE:PFE) Receives $50.38 Consensus Target Price from Analysts

March 30, 2023 | seekingalpha.com

Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future

March 27, 2023 | finance.yahoo.com

As Covid-19 shot sales dwindle, BioNTech doubles down on cancer vaccines

March 27, 2023 | finance.yahoo.com

Bear of the Day: Pfizer Inc. (PFE)

March 27, 2023 | finance.yahoo.com

BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook.

March 27, 2023 | finance.yahoo.com

BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion

March 26, 2023 | finance.yahoo.com

Chinese Foreign Minister Qin Gang assures US business leaders of Beijing's support

March 26, 2023 | seekingalpha.com

How a cheap diabetes pill could impact sales of Pfizer's COVID antiviral Paxlovid

March 25, 2023 | fool.com

This Cancer Drug Candidate Could Be a Hit for Pfizer

March 25, 2023 | fool.com

Can This New Drug Boost Pfizer's Stock?

March 24, 2023 | finance.yahoo.com

GSK, Haleon Shares Drop After Setback on Zantac Cancer Litigation

March 24, 2023 | cnbc.com

Pfizer's Covid drug Paxlovid may reduce the risk of developing long Covid, study says

March 23, 2023 | benzinga.com

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Company Calendar

Ex-Dividend for 3/3 Dividend: 1/26/2023
Last Earnings: 1/31/2023
Dividend Payable: 3/03/2023
Today: 3/31/2023
Next Earnings (Estimated): 5/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:PFE
CUSIP: 71708110
CIK: 78003
Web: www.pfizer.com
Phone: (212) 733-2323
Fax: 302-655-5049
Employees: 83,000
Year Founded: 1849

Price Target and Rating

Average Stock Price Forecast: $50.38
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $40.00
Forecasted Upside/Downside: +24.8%
Consensus Rating: Hold
Rating Score (0-4): 2.36
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.48
Trailing P/E Ratio: 7.37
Forward P/E Ratio: 12.23
P/E Growth: 1.35
Net Income: $31.37 billion
Net Margins: 31.27%
Pretax Margin: 34.62%
Return on Equity: 42.03%
Return on Assets: 19.55%

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 1.22
Quick Ratio: 1.00

Sales & Book Value

Annual Sales: $100.33 billion
Price / Sales: 2.27
Cash Flow: $7.69 per share
Price / Cash Flow: 5.25
Book Value: $17.09 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 5,644,400,000
Free Float: 5,641,580,000
Market Cap: $227.86 billion
Optionable: Optionable
Beta: 0.64

Social Links

Key Executives

Albert Bourla
Chairman & Chief Executive Officer

David M. Denton
Chief Financial Officer & Executive Vice President

Annaliesa Anderson
SVP, Head-Vaccine Research & Development

Mikael Dolsten
Co-Chief Scientific Officer & President-Research

Jeff Settleman
Co-Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PFE Stock - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View PFE analyst ratings or view top-rated stocks.
What is Pfizer's stock price forecast for 2023?: 14 Wall Street analysts have issued 12 month price objectives for Pfizer's shares. Their PFE share price forecasts range from $40.00 to $75.00. On average, they predict the company's share price to reach $50.38 in the next year. This suggests a possible upside of 24.8% from the stock's current price.
View analysts price targets for PFE or view top-rated stocks among Wall Street analysts.
How have PFE shares performed in 2023?: Pfizer's stock was trading at $51.24 on January 1st, 2023. Since then, PFE stock has decreased by 21.2% and is now trading at $40.37.
View the best growth stocks for 2023 here.
When is Pfizer's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PFE earnings forecast.
How were Pfizer's earnings last quarter?: Pfizer Inc. (NYSE:PFE) posted its quarterly earnings data on Tuesday, January, 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The biopharmaceutical company had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a net margin of 31.27% and a trailing twelve-month return on equity of 42.03%. The business's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.08 earnings per share.
Read the conference call transcript.
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?: Pfizer announced a quarterly dividend on Friday, December 9th. Shareholders of record on Friday, January 27th will be paid a dividend of $0.41 per share on Friday, March 3rd. This represents a $1.64 annualized dividend and a dividend yield of 4.06%. The ex-dividend date is Thursday, January 26th. This is a positive change from the stock's previous quarterly dividend of $0.40.
Read our dividend analysis for PFE.
What ETFs hold Pfizer's stock?: ETFs with the largest weight of Pfizer (NYSE:PFE) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), iShares Core High Dividend ETF (HDV), Pacer US Cash Cows Growth ETF (BUL), VanEck Pharmaceutical ETF (PPH), Health Care Select Sector SPDR Fund (XLV), iShares U.S. Healthcare ETF (IYH), SPDR S&P Pharmaceuticals ETF (XPH) and WisdomTree U.S. High Dividend Fund (DHS).
Is Pfizer a good dividend stock?: Pfizer (NYSE:PFE) pays an annual dividend of $1.64 per share and currently has a dividend yield of 4.10%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 29.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PFE will have a dividend payout ratio of 43.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.
What guidance has Pfizer issued on next quarter's earnings?: Pfizer updated its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $3.25-$3.45 for the period, compared to the consensus estimate of $4.38. The company issued revenue guidance of $67.0-$71.0 billion, compared to the consensus revenue estimate of $74.23 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?: 358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Pfizer own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).
What is Pfizer's stock symbol?: Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
Who are Pfizer's major shareholders?: Pfizer's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Moneta Group Investment Advisors LLC (2.87%), Geode Capital Management LLC (1.95%), Morgan Stanley (1.42%), Charles Schwab Investment Management Inc. (1.31%), Norges Bank (1.10%) and Dimensional Fund Advisors LP (0.75%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Ronald E Blaylock and William R Carapezzi Jr.
View institutional ownership trends.
How do I buy shares of Pfizer?: Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pfizer's stock price today?: One share of PFE stock can currently be purchased for approximately $40.37.
How much money does Pfizer make?: Pfizer (NYSE:PFE) has a market capitalization of $227.86 billion and generates $100.33 billion in revenue each year. The biopharmaceutical company earns $31.37 billion in net income (profit) each year or $5.48 on an earnings per share basis.
How many employees does Pfizer have?: The company employs 83,000 workers across the globe.
Does Pfizer have any subsidiaries?: The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alpharma Pharmaceuticals LLC, American Food Industries LLC, Amplyx Pharmaceuticals, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Arena, Array BioPharma, Array BioPharma Inc., BIND Therapeutics Inc., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Blue Whale Re Ltd., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Covx, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Farminova Produtos Farmaceuticos de Inovacao Lda., FoldRx Pharmaceuticals LLC, Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Hospira, Hospira Adelaide Pty Ltd, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Limited, Hospira Philippines Inc., Hospira Pte. Ltd., Hospira Puerto Rico LLC, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, John Wyeth & Brother Limited, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Laboratoires Pfizer S.A., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, P-D Co. LLC, PAH USA IN8 LLC, PBG Puerto Rico LLC, PF Argentum Acquisition ULC, PF Consumer Healthcare Holdings LLC, PF Consumer Healthcare Holdings US Inc., PF Czech Republic Holdings B.V., PF Finland Holdings B.V., PF OFG Ireland 2 B.V., PF OFG South Korea 1 B.V., PF OFG South Korea 2 B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings B.V., PF PRISM IMB B.V., PFE Wyeth-Ayerst (Asia) LLC, PFIZER (VIETNAM) LIMITED COMPANY, PHIVCO Corp., PHIVCO Holdco S.à r.l., PIMB OFG Spain Holding S.L., PRISM Holdings B.V., PT. Pfizer Indonesia, Parke Davis & Company LLC, Parke Davis Limited, Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Ltd, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Afrique de L'Ouest, Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty Ltd, Pfizer Australia Pty Ltd, Pfizer B.V., Pfizer Biopharma Egypt LLC, Pfizer Biopharmaceuticals Egypt LLC, Pfizer Bolivia S.A., Pfizer Canada ULC / Pfizer Canada SRI, Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Consumer Healthcare, Pfizer Cork Limited, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Corporation S. de R.L., Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development B.V., Pfizer Development LLC, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Europe MA EEIG, Pfizer Export B.V., Pfizer Export Company, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare India Private Limited, Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holdings Corporation, Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer International LLC, Pfizer International Operations, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Japan Inc., Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Holding B.V., Pfizer New Zealand Limited, Pfizer North America Services LLC, Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE CIA. Ltda., Pfizer PFE Eastern Investments B.V., Pfizer PFE Global Holdings B.V., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Service Company Holding B.V., Pfizer PFE Spain B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals Science and Technology Co. Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer R&D Holding B.V., Pfizer R&D Japan G.K., Pfizer R&D UK Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SA (Belgium), Pfizer SRB d.o.o., Pfizer Saudi Limited, Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Specialties Limited, Pfizer Trading Polska sp.z.o.o., Pfizer Transactions LLC, Pfizer Tunisie SA, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Ventures (US) LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, ReViral, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig S.A., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Solinor LLC, Sugen LLC, Tabor LLC, Therachon, Trillium Therapeutics, Trillium Therapeutics ULC, Trillium Therapeutics USA LLC, Upjohn Laboratorios Lda., Vicuron Holdings LLC, W-L LLC, Warner Lambert, Warner Lambert del Uruguay S.A., Warner-Lambert Company GmbH, Warner-Lambert Company LLC, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Pakistan Limited, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth-Ayerst (Asia) LLC, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
How can I contact Pfizer?: Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The official website for the company is www.pfizer.com. The biopharmaceutical company can be reached via phone at (212) 733-2323 or via fax at 302-655-5049.

This page (NYSE:PFE) was last updated on 3/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pfizer - PFE Stock Forecast, Price & News

Pfizer MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Pfizer (NYSE:PFE) Stock

PFE Stock News Headlines

PFE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PFE Stock - Frequently Asked Questions

Overall MarketRank^™